文献速递细菌感染、耐药与抗菌药物

暴露于世界卫生组织AWaRe分类抗生素与多重耐药菌分离:系统综述与荟萃分析

Exposure to World Health Organization's AWaRe antibiotics and isolation of multidrug resistant bacteria: a systematic review and meta-analysis.
PubMed 文献 · Clin Microbiol Infect · 2022-03-23

该研究系统检索截至2020年8月20日的文献,纳入349项观察性研究,评估既往暴露于WHO AWaRe分类(Access、Watch、Reserve)抗生素与WHO优先病原体列表中关键及高优先级多重耐药菌(MDRO)分离的关联。结果显示,几乎所有AWaRe类别抗生素暴露均与MDRO定植/感染呈统计学显著关联,Watch和Reserve类抗生素的比值比(OR)高于Access类;第一代头孢菌素(Access)关联最低(58项研究;OR=1.2,95%CI:1.0-1.4),利奈唑胺(Reserve)关联最强(22项研究;OR=2.6,95%CI:2.1-3.1),碳青霉烯类(Watch)次之(237项研究;OR=2.3,95%CI:2.1-2.5)。所有抗生素/MDRO关联均存在高异质性。

要点

  • 几乎所有AWaRe类别抗生素暴露均与MDRO定植/感染呈统计学显著关联。
  • Watch和Reserve类抗生素的OR高于Access类。
  • 第一代头孢菌素(Access)关联最低,利奈唑胺(Reserve)关联最强。

核心结论

  • 优化Access类抗生素的使用可能减少MDRO选择及全球抗生素耐药。
  • 尽管数据存在局限性,本研究为进一步采用AWaRe作为改善全球抗生素使用的重要工具提供了有力依据。

研究设计与样本

  • 系统综述与荟萃分析,检索Embase、Ovid Medline、Scopus、Cochrane系统综述数据库、Cochrane对照试验中心注册库及ClinicalTrials.gov(自建库至2020年8月20日)。
  • 纳入评估MDRO感染/定植风险的病例对照、队列或实验研究,对象为任何年龄和性别的住院或门诊患者。
  • 共纳入349项符合条件的研究,均为观察性研究。

主要发现

  • 既往暴露于几乎所有AWaRe类别抗生素/类别均与任何MDRO定植/感染呈统计学显著关联。
  • 第一代头孢菌素(Access)与任何MDRO定植/感染的关联最低(58项研究;OR=1.2,95%CI:1.0-1.4)。
  • 利奈唑胺(Reserve)的关联最强(22项研究;OR=2.6,95%CI:2.1-3.1),其次为碳青霉烯类(Watch)(237项研究;OR=2.3,95%CI:2.1-2.5)。
  • 观察到的Watch和Reserve类抗生素的OR高于Access类抗生素。
  • 所有抗生素/MDRO关联均存在高异质性。

关键数值与推荐

  • 所有纳入研究均为观察性研究,易受设计偏倚影响且缺乏对混杂因素的调整,并非主要设计用于比较AWaRe类别间的关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有纳入研究均为观察性研究,易受设计偏倚影响且缺乏对混杂因素的调整。
  • 纳入研究并非主要设计用于比较AWaRe类别间的关联。
  • 所有抗生素/MDRO关联均存在高异质性。
  • 原文指出数据存在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibiotic use drives antibiotic resistance. OBJECTIVES: To systematically review the literature and estimate associations between prior exposure to antibiotics across World Health Organization's (WHO) AWaRe categories (Access, Watch, Reserve) and isolation of critical and high-priority multidrug resistant organisms (MDROs) on the WHO priority pathogen list. DATA SOURCES: Embase, Ovid Medline, Scopus, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov (from inception to 20/08/2020). STUDY ELIGIBILITY CRITERIA: Case-control, cohort, or experimental studies that assessed the risk of infection/colonization with MDROs. PARTICIPANTS: Inpatients or outpatients of any age and sex. INTERVENTIONS: Prior exposure to antibiotics that could be categorized into the AWaRe framework. DATA ANALYSIS: Tailored design-specific checklists applied to each included study. For each antibiotic/class, crude odds ratios (ORs) were pooled through random-effects meta-analyses, both overall and by MDRO. Heterogeneity was examined. RESULTS: We identified 349 eligible studies. All were observational, prone to bias due to design and lack of adjustment for confounding, and not primarily designed to compare associations across AWaRe categories. We found statistically significant associations between prior exposure to almost all antibiotics/classes across AWaRe categories and colonization/infection with any MDRO. We observed higher ORs for Watch and Reserve antibiotics than with Access antibiotics. First generation cephalosporins (Access) had the least association with any MDRO colonization/infection (58 studies; OR = 1.2 [95% CI: 1.0-1.4]), whereas strongest associations were estimated for linezolid (Reserve) (22 studies; OR = 2.6 [95% CI: 2.1-3.1]), followed by carbapenems (Watch) (237 studies; OR = 2.3 [95% CI: 2.1-2.5]). There was high heterogeneity for all antibiotic/MDRO associations. CONCLUSIONS: Optimising use of Access antibiotics is likely to reduce the selection of MDROs and global antibiotic resistance. Despite data limitations, our study offers a strong rationale for further adoption of AWaRe as an important tool to improve antibiotic use globally.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Sulis G, Sayood S, Katukoori S, et al. Exposure to World Health Organization's AWaRe antibiotics and isolation of multidrug resistant bacteria: a systematic review and meta-analysis. Clin Microbiol Infect. 2022. PMID: 35339675. doi:10.1016/j.cmi.2022.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。